[over 12 months (P<0.001)]
[over 12 months (P<0.001)]
Several clinical organizations, including the ADA and AACE, have published guidelines for the use of CGM in the management of diabetes20,21. Highlights from the published guidelines are included below.
American Diabetes Association (ADA)
The ADA published diabetes treatment guidelines as part of the 2022 Standards of Medical Care in Diabetes20, making the following clinical and access recommendations specific to FreeStyle Libre Personal CGMs:
American Association of Clinical Endocrinologists (AACE)
The AACE published recommendations in 202121, regarding the use of CGMs in the management of people with diabetes. The following recommendations were highlighed with respect to continuous glucose monitoring:
Recommendations from the ADA and AACE on CGM Metrics:
For therapeutic CGM, the following codes are applicable24:
At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.
Medicare coverage is available for the FreeStyle Libre 2 system if the FreeStyle Libre 2 reader is used to review glucose data on some days every month. Medicare and other third party payor criteria apply.
Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.
FreeStyle Libre 2 and FreeStyle Libre 3 systems are indicated for use in people with diabetes age 4 and older.
* Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.
‡ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.
§ Represents percentage of people experiencing a diabetes-related hospital admission.
|| Represents inpatient events or emergency outpatient events for hypoglycemia, hyperglycemia, diabetic ketoacidosis, or hyperosmolarity.
¶ Compared to Dexcom.
# Given that the coverage criteria of CGM for Medicare, the Veterans Administration, Department of Defense, and Indian Health Services is governed at the federal level through policy decisions, a budget impact analysis was not completed for persons covered by these payers.
** Cost savings results from removal of manual prior authorization (PA) process. Under pharmacy benefit, PAs can either be eliminated or automated via smart PA.
†† Does not apply to Medicare and Medicaid.
References: 1. FreeStyle Libre 2 AMCP Dossier 2. Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610 3. Fokkert, M. BMJ Open Diabetes Res Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809 4. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013 5. Bolinder, J. The Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5 6. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6 7. Miller E, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780 8. Tyndall, V. Diabetologia (2019): https://doi.org/10.1007/s00125-019-4894-1 9. Evans M, et al. Diabetes Therapy (2022): https://doi.org/10.1007/s13300-022-01253-9 10. Wright, E. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069 11. Kroger, J. Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00741-9 12. Carlson AL, et al. BMJ Open Diabetes Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590 13. Campbell, F. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735 14. Kerr M, et al. Poster presented at the ATTD Conference, Madrid, Spain, February 19-22, 2020. https://doi.org/10.1089/dia.2020.2525.abstracts 15. Deshmukh, H. Diabetes Care (2020): https://doi.org/10.2337/dc20-0738 16. Frank, JR. Diabetes Technol Ther (2021): https://doi.org/10.1089/dia.2021.0263 17. Miller E, et al. Am J Med Open (2022): https://doi.org/10.1016/j.ajmo.2022.100008 18. Battelino, T. Diabetes Care (2019): https://doi.org/10.2337/dci19-0028 19. Vigersky, RA. Diabetes Technol Ther (2019): https://doi.org/10.1089/dia.2018.0310 20. ADA Standards of Medical Care in Diabetes. Diabetes Care (2022): https://doi.org/10.2337/dc22-S007 21. Grunberger G, et al. Endocr Pract (2021): https://doi.org/10.1016/j.eprac.2021.04.008 22. ADA Standards of Medical Care in Diabetes. Diabetes Care (2022): https://doi.org/10.2337/dc22-S006 23. First DataBank, June 2022. 24. Centers for Medicare & Medicaid Services. CMS Local Coverage Article A52464. Revision Effective July 18, 2021. Accessed February 02, 2022. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52464
ADC-52428 v2.0 06/22
Payer.freestylelibre.us/en is a product-specific website intended only for residents of the United States.
If you are a resident of another country, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.
ADC-21099 v3.0 07/21